Castle Biosciences, Inc. (Nasdaq: CSTL) announced unaudited preliminary performance results for Q4 and full-year 2025.
Q4 2025 total revenue expected to exceed $340 million.
Year-end 2025 cash, cash equivalents, and marketable investment securities expected to be approximately $300 million.
Total Revenue Exceeds Expectations
2025 total revenue projected to surpass $340 million, exceeding the guided range of $327-335 million.
Core Revenue Drivers Growth
Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) up by 37% in 2025 compared to 2024.
New Test Launch Success
AdvanceAD-Tx™ new test launched in Nov. 2025 showing strong adoption with over 50% of granted clinician offices ordering within the first five weeks.
- Strong Q4 and full-year 2025 results indicate successful execution and leadership in dermatologic and gastrointestinal franchises.
- Company positioned well with a strong balance sheet to capitalize on growth opportunities in 2026.
- Limited access launch of AdvanceAD-Tx™ expands the total addressable market for Castle Biosciences.
Castle Biosciences achieved remarkable results in Q4 and full-year 2025, showcasing growth and innovation in their test portfolio. Their strong position and successful launches set the stage for continued success in 2026 and beyond.